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-3 -Carpal tunnel syndrome (CTS) is the commonest entrapment neuropathy complicating diabetes (1) , with an incidence several-fold that in the general population (1) (2) (3) . Based on clinical/electrophysiological assessment (4) , one-third of type 2 patients have CTS and one-sixth of these report symptoms. Conventional treatments comprise splinting, diuretics and corticosteroid injections, and carpal tunnel decompression (CTD) if conservative measures fail (2) . Open and endoscopic CTD have equivalent outcomes (5) , with 75% of cases cured or minimally symptomatic (6) regardless of diabetes status (7) . There are, however, few epidemiologic data relating to CTD in diabetes. In the general population, 0.4-1.4 decompressions are conducted per 1,000 person-years (3) but the relative CTS prevalence suggests a higher rate in diabetes. Our aim was, therefore, to determine the incidence and predictors of CTD in well-characterized type 2 patients.
RESEARCH DESIGN AND METHODS-The Fremantle Diabetes Study (FDS) was a
longitudinal observational study in a community of 120,097 people (8) . Of 2,258 diabetic patients identified between 1993 and 1996, 1,426 (63%) were recruited and 1,294 had type 2 diabetes. The FDS protocol was approved by the Fremantle Hospital Human Rights Committee. All subjects gave informed consent before participation. Baseline and annual reviews comprised a detailed questionnaire, physical examination and biochemical tests on fasting blood/urine samples (8) . Complications were identified using standard criteria (9) . RESULTS-There were 1,284 type 2 FDS subjects without a self-reported/WADLSdocumented CTD at baseline. Sixty-seven (5.8%) had a first CTD during 12,109 (mean 9.4±3.7) years, an incidence of 5.5/1,000 patient-years. Men and women had a similar incidence (5.8 vs 5.3/1,000 patient-years; P = 0.74). Eighteen patients (26.9%) had at least two CTDs during follow-up, representing re-operation or decompression in the opposite hand. CTD was performed in a private facility in 76.1% of cases.
In the WA population, 32,836 people had a CTD during 25,226,010 person-years, or 1.30/1000 person-years (95% confidence interval (CI), 1.29-1.32). The CTD incidence in the FDS subgroup was, therefore, 4.2 times higher (P < 0.001), but this is a conservative relative rate since the general population incidence does not exclude further CTDs in the same patient.
Baseline univariate determinants of incident first CTD are shown in the 11-3 .74]; P ≤ 0.021).
-5 -CONCLUSIONS-The crude incidence of first CTD in our type 2 patients is between 4 and 14 times published general population figures (3) and at least 4.2 times that in the WA population. This difference parallels the three-fold increased risk of CTS in type 2 diabetes (11, 12) . Consistent with a general population study that identified obesity as a strong associate of CTD (13), a 1 kg/m 2 increase in baseline BMI increased the likelihood of CTD in our patients by 5%. Unlike other studies of CTS determinants in generalpopulation (1, 2, 14, 15) and diabetes-specific (4, 12, (16) (17) (18) (19) ) studies, we did not find that baseline age, gender, diabetes duration, arthritis, microangiopathy, smoking or thyroid disease predicted CTD.
Our data suggest that socio-demographic factors are important determinants of CTD in type 2 diabetes. The relationship with marital status could reflect a partner's influence on the decision to pursue CTD. In addition, the ability to pay for a private operation (given long public waiting lists) would be greater with multiple income sources, consistent with the univariate inverse association between household income and CTD in our data. However, the apparent importance of socio-demographic factors compared with recognized CTS associates in diabetes (4, 12, (16) (17) (18) (19) might also indicate that variables such as older age and vascular complications are contraindications to surgery.
Since indications for lipid-lowering therapy in diabetes were less inclusive during FDS recruitment than subsequently (20) , baseline use of these agents could have been a surrogate for general treatment-seeking behaviour including CTD. Uptake of lipidlowering therapy increased four-fold during the FDS and there are case reports linking these drugs to neuropathy (21) . However, such reports are rare and do not include CTS.
Hypercholesterolemia may increase CTS risk (22) and it is possible that dyslipidemic patients were commenced on lipid-lowering therapy after experiencing significant -6 -cholesterol-induced median nerve enlargement (22) , with a subsequent paradoxical association between statin/fibrate use and CTD incidence.
Our study had limitations. We had no data on the prevalence and incidence of CTS, indication(s) for operation or relative frequency of clinical review that would have facilitated a more detailed analysis of the high CTD incidence compared to that in the general population. Nevertheless, our findings reflect the relative CTS prevalence in diabetes found previously (1) (2) (3) . Strengths of the WADLS include its low coding error rate (23) and stable population base (24) .
Because of its high prevalence (4), we recommend that CTS assessment for symptoms and signs of median nerve dysfunction should be part of regular complications screening in all type 2 patients. The present data suggest that many patients with CTS will require CTD for symptom relief. 
